Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1 [0.03%]
Donavanix单抗联合Zimbrilimab一线治疗PD-L1高表达晚期非小细胞肺癌患者的疗效：来自随机II期ARC-10研究（Part1）
Jarushka Naidoo,Solange Peters,Yotsawaj Runglodvatana et al.
Jarushka Naidoo et al.
Introduction: TIGIT and PD-1 trigger distinct but interconnected immunosuppressive pathways. We investigated first-line domvanalimab (Fc-silent anti-TIGIT) plus zimberelimab (anti-PD-1) in PD-L1-high (≥50%), stage IIIB-I...
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study [0.03%]
表皮生长因子受体突变状态、治疗模式及可切除早期非小细胞肺癌真实世界患者的辅助表皮生长因子受体酪氨酸激酶抑制剂获批前后的预后：一项国际真实世界研究
Steven H Lin,Doreen A Kahangire,Saurabh P Nagar et al.
Steven H Lin et al.
Objectives: Historically, resection followed by chemotherapy was standard treatment for stage II-III non-small cell lung cancer (NSCLC) and selected patients with stage IB disease. However, recurrence was common post-rese...
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1 [0.03%]
安罗替尼联合特瑞普利单抗维持治疗广泛期小细胞肺癌的临床疗效及安罗替尼诱导神经内分泌分化抑制的机制研究（NOTCH1信号通路）
Dongqing Lv,Ruiqing Zhu,Guixian Wu et al.
Dongqing Lv et al.
Purpose: To evaluate the efficacy, safety and underlying mechanisms of toripalimab combined with anlotinib as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) who achieved disease cont...
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study [0.03%]
广泛期小细胞肺癌免疫治疗再挑战的现实世界回顾性研究
Jingyi Wang,Yuling Zhong,Bolin Chen et al.
Jingyi Wang et al.
Background: Although extensive-stage small cell lung cancer (ES-SCLC) is susceptible to first-line immunotherapy combined with chemotherapy (immunochemotherapy), most patients experience relapse and resistance after initi...
Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort [0.03%]
基于真实世界队列的联合DNA和RNA测序在非鳞状非小细胞肺癌中检测到更多的NRG1融合基因
Breno Jeha Araújo,Filipe Visani,Rafael Duarte Paes et al.
Breno Jeha Araújo et al.
Background: NRG1 gene fusions are rare oncogenic drivers in non-squamous NSCLC, occurring in approximately 0.2-0.3% of cases and enriched in invasive mucinous adenocarcinoma (IMA). Their true incidence may be underestimat...
Respiratory sarcopenia and prehabilitation in thoracic oncology: Diagnostic approaches and clinical implications [0.03%]
胸部肿瘤呼吸系统肌肉减少症与康复先驱疗法：诊断方法和临床意义
David Dávila-Dupont,Marisol Arroyo-Hernández,Jenny G Turcott et al.
David Dávila-Dupont et al.
Respiratory sarcopenia (RS) is increasingly considered in thoracic oncology because reduced strength and cough effectiveness may relate to perioperative pulmonary complications, symptom burden, and treatment tolerance. However, definitions,...
Osimertinib dose-reduction issues in EGFR-mutated metastatic NSCLC [0.03%]
EGFR突变转移性NSCLC患者使用奥希替尼减量问题
Tian Xia,Yi Zhang,Liang Zheng
Tian Xia
Volume and location of screen-detected lung nodules associated with lung cancer within two-year follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) trial [0.03%]
英国肺癌筛查(UKLS)试验的次级分析：两年随访期内与肺癌相关的肺结节体积和位置
Oke Dimas Asmara,Harriet L Lancaster,John K Field et al.
Oke Dimas Asmara et al.
Introduction: Follow-up of radiologically suspicious lung nodules from screening programs remains complex and unstandardized. This study analyses distribution and characteristics of solid and part-solid non-calcified nodu...
SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules [0.03%]
SGLT2抑制剂的使用可减少持续性肺结节的发展和手术干预
Katherine Ortmeyer Welch,Kelly A McGovern,Lydia Chen et al.
Katherine Ortmeyer Welch et al.
Objective: In-situ and early-stage cancers are the fastest growing subset of pulmonary malignancies, often presenting as persistent nodules and ground glass opacities. These lesions are frequently surveilled, though many ...
Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial [0.03%]
Ⅲ期IFCT-0302临床试验中肺部局部非小细胞肺癌患者手术切除后的预后因素——俱乐部细胞分泌蛋白(CCSP)血清浓度是一项预测指标
Solenn Brosseau,Harry Etienne,Katell Peoc&#x;h et al.
Solenn Brosseau et al.
Introduction: No specific follow-up strategy has shown to improve overall survival (OS) after surgical resection of non-small cell lung cancer (NSCLC). Club cell secretory protein (CCSP) is produced by bronchiolar club ce...